The expression of IgG allotypes on platelets and immunization to IgG allotypes in multitransfused thrombocytopenic patients

Thomas Stephen Kickler, Paul Michael Ness, Hayden G. Braine, Lisa Richardson, Mary Farkosh

Research output: Contribution to journalArticle

Abstract

We investigated whether the platelet-membrane surface carries IgG allotypic antigens and whether these determinants may be important in platelet transfusion therapy. Using a hemagglutination inhibition assay, we showed that the G1 m IgG allotypes (a, x, f) and K1m and K3m light-chain allotypes are expressed on the surface of platelets, whereas G3m allotype antigenic determinants were not detectable. In 146 multitransfused thrombocytopenic patients, 35 (24%) patients were found to have antiallotypic antibodies. To study the effect of antiallotypic antibodies on platelet transfusion outcome, patients received platelet transfusions from donors, either positive or negative for the IgG allotype to which patients were immunized. Of the 19 antigen-positive and 19 antigen-negative platelet transfusions given, respectively, the mean platelet count increments at 1 hour were 8,402 ± 6,721 (1 SD) and 9,799 ± 5,559 (1 SD) P <.2. Transfusion reactions were not more common when antigen-positive platelet transfusions were given. Despite the presence of IgG allotypic determinants on platelets, allotypic antibodies do not decrease platelet transfusion recovery. Furthermore, passive administration of plasma containing IgG allotypes to patients with antiallo-typic antibodies does not lead to innocent bystander-mediated platelet destruction.

Original languageEnglish (US)
Pages (from-to)849-852
Number of pages4
JournalBlood
Volume76
Issue number4
StatePublished - Aug 15 1990

Fingerprint

Immunization
Platelet Transfusion
Platelets
Blood Platelets
Immunoglobulin G
Antigens
Antibodies
Immunoglobulin Allotypes
Hemagglutination
Platelet Count
Epitopes
Tissue Donors
Light
Membranes
Assays

ASJC Scopus subject areas

  • Hematology

Cite this

The expression of IgG allotypes on platelets and immunization to IgG allotypes in multitransfused thrombocytopenic patients. / Kickler, Thomas Stephen; Ness, Paul Michael; Braine, Hayden G.; Richardson, Lisa; Farkosh, Mary.

In: Blood, Vol. 76, No. 4, 15.08.1990, p. 849-852.

Research output: Contribution to journalArticle

@article{45f0d0aea70f49bc9fedbd2dbf962db4,
title = "The expression of IgG allotypes on platelets and immunization to IgG allotypes in multitransfused thrombocytopenic patients",
abstract = "We investigated whether the platelet-membrane surface carries IgG allotypic antigens and whether these determinants may be important in platelet transfusion therapy. Using a hemagglutination inhibition assay, we showed that the G1 m IgG allotypes (a, x, f) and K1m and K3m light-chain allotypes are expressed on the surface of platelets, whereas G3m allotype antigenic determinants were not detectable. In 146 multitransfused thrombocytopenic patients, 35 (24{\%}) patients were found to have antiallotypic antibodies. To study the effect of antiallotypic antibodies on platelet transfusion outcome, patients received platelet transfusions from donors, either positive or negative for the IgG allotype to which patients were immunized. Of the 19 antigen-positive and 19 antigen-negative platelet transfusions given, respectively, the mean platelet count increments at 1 hour were 8,402 ± 6,721 (1 SD) and 9,799 ± 5,559 (1 SD) P <.2. Transfusion reactions were not more common when antigen-positive platelet transfusions were given. Despite the presence of IgG allotypic determinants on platelets, allotypic antibodies do not decrease platelet transfusion recovery. Furthermore, passive administration of plasma containing IgG allotypes to patients with antiallo-typic antibodies does not lead to innocent bystander-mediated platelet destruction.",
author = "Kickler, {Thomas Stephen} and Ness, {Paul Michael} and Braine, {Hayden G.} and Lisa Richardson and Mary Farkosh",
year = "1990",
month = "8",
day = "15",
language = "English (US)",
volume = "76",
pages = "849--852",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - The expression of IgG allotypes on platelets and immunization to IgG allotypes in multitransfused thrombocytopenic patients

AU - Kickler, Thomas Stephen

AU - Ness, Paul Michael

AU - Braine, Hayden G.

AU - Richardson, Lisa

AU - Farkosh, Mary

PY - 1990/8/15

Y1 - 1990/8/15

N2 - We investigated whether the platelet-membrane surface carries IgG allotypic antigens and whether these determinants may be important in platelet transfusion therapy. Using a hemagglutination inhibition assay, we showed that the G1 m IgG allotypes (a, x, f) and K1m and K3m light-chain allotypes are expressed on the surface of platelets, whereas G3m allotype antigenic determinants were not detectable. In 146 multitransfused thrombocytopenic patients, 35 (24%) patients were found to have antiallotypic antibodies. To study the effect of antiallotypic antibodies on platelet transfusion outcome, patients received platelet transfusions from donors, either positive or negative for the IgG allotype to which patients were immunized. Of the 19 antigen-positive and 19 antigen-negative platelet transfusions given, respectively, the mean platelet count increments at 1 hour were 8,402 ± 6,721 (1 SD) and 9,799 ± 5,559 (1 SD) P <.2. Transfusion reactions were not more common when antigen-positive platelet transfusions were given. Despite the presence of IgG allotypic determinants on platelets, allotypic antibodies do not decrease platelet transfusion recovery. Furthermore, passive administration of plasma containing IgG allotypes to patients with antiallo-typic antibodies does not lead to innocent bystander-mediated platelet destruction.

AB - We investigated whether the platelet-membrane surface carries IgG allotypic antigens and whether these determinants may be important in platelet transfusion therapy. Using a hemagglutination inhibition assay, we showed that the G1 m IgG allotypes (a, x, f) and K1m and K3m light-chain allotypes are expressed on the surface of platelets, whereas G3m allotype antigenic determinants were not detectable. In 146 multitransfused thrombocytopenic patients, 35 (24%) patients were found to have antiallotypic antibodies. To study the effect of antiallotypic antibodies on platelet transfusion outcome, patients received platelet transfusions from donors, either positive or negative for the IgG allotype to which patients were immunized. Of the 19 antigen-positive and 19 antigen-negative platelet transfusions given, respectively, the mean platelet count increments at 1 hour were 8,402 ± 6,721 (1 SD) and 9,799 ± 5,559 (1 SD) P <.2. Transfusion reactions were not more common when antigen-positive platelet transfusions were given. Despite the presence of IgG allotypic determinants on platelets, allotypic antibodies do not decrease platelet transfusion recovery. Furthermore, passive administration of plasma containing IgG allotypes to patients with antiallo-typic antibodies does not lead to innocent bystander-mediated platelet destruction.

UR - http://www.scopus.com/inward/record.url?scp=0025148758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025148758&partnerID=8YFLogxK

M3 - Article

VL - 76

SP - 849

EP - 852

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -